NAD Dependent Protein Deacetylase Sirtuin 1: Significant Pipeline Review for the First Half of 2017


Published on : Jun 23, 2017

Albany, New York, June 23, 2017: The NAD dependent protein deacetylase Sirtuin 1 market is growing since key related pharmaceutical markets are dependent entirely over it. Looking into this opportunity, a new study has been included into the vast online repository of Market Research Hub (MRH), with title, ‘’ NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Pipeline Review, H1 2017‘’. The report strives to contribute a precise analysis of the most profitable factors such as major drug profiles, leading companies and careful pipeline review data.

Today, the NAD dependent protein deacetylase Sirtuin 1 is a medicine used by many patients of fatty liver disease, steatohepatitis, diabetes, pneumonia, COPD and several types of cancers. The study begins with a significant introduction, product overview together with the therapeutics development. In this section, the report also evaluates the useful products under development in terms of therapy area, indication, companies as well as the universities and institutes. Accordingly, the report offers vital facts about the preclinical and discovery stages within universities for the benefit of the buyer.

Another important part of the report describes major products from therapy areas for major diseases in oncology, gastrointestinal, metabolic disorders, central nervous system, and genetic disorders alongside the infectious and respiratory diseases which contains indications. Together, the study analyzes the other disorders such as nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes, bacterial pneumonia, chronic myelocytic leukemia (CML, Chronic Myeloid Leukemia), chronic obstructive pulmonary disease (COPD), emphysema, Ewing sarcoma, pancreatic cancer, Parkinson's disease, peritonitis, solid tumor and spinocerebellar ataxia (SCA).

Additionally, the report analyzes drug profiles for the pipeline products which contains useful topics such as product description, licensing and collaboration data together with other new developments. Some of the popular drugs evaluated in this pipeline analysis are the SIRT1, JOT-104, JOT-105, resveratrol and SRT-3025. Such drug-wise data helps the reader to involve in premium research for creating better products.

Click here to get more info with TOC in a PDF Format : http://www.marketresearchhub.com/enquiry.php?type=S&repid=1157706

The report reviews key players involved in the production of this powerful medicine and enlists all their major and minor projects. Some of the major companies involved in this report are NuSirt Biopharma, Bial - Portela and Ca SA, GlaxoSmithKline Plc and Jyant Technologies Inc. Thus, the study introspects all the huge companies and their strategies as well as research data to help new investors gain higher revenues.

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top